| Document |
Document Title |
|
JP4836396B2 |
The invention relates to novel naphthalene derivatives of formula (I) and their use as cannabinoid receptor agonists wherein X, R 1 , R 2 and R 3 are as defined in the description, processes for their production, their use as pharmaceuti...
|
|
JP4824740B2 |
The present invention is related to novel intermediates and processes which are useful in the preparation of certain antihistaminic piperidine derivatives of formula (I) wherein W represents -C(=O)- or -CH(OH)-; R 1 represents hydrogen o...
|
|
JP4819210B2 |
The use of hydroxylated carboxylic acid esters and amides as stabilizers is new. Certain of the hydroxylated carboxylic acid esters are also new. The hydroxylated carboxylic acid esters and amides are compounds of formula (I): R<1> = H; ...
|
|
JP4814318B2 |
Para-tertiary-butyl calix [6] arene is new. Para-tertiary-butyl calix [6] arene (I) of formulae (Ia) or (Ib) is new. R 1, R 3, R 5 = acetyl, amino, phosphate, NO 2, sulfate, carboxylic, (thio)carboxy, (thio)carbamate, 1-60C (preferably 1...
|
|
JP4805916B2 |
Provided are compounds of Formula V and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders.
|
|
JP4776784B2 |
|
|
JP4769248B2 |
Compounds of the formula: are described in which Z, Q, X, L, m and n assume the meanings stated in the description. The compounds (I) inhibit the production of TNF alpha and may thus be useful in the treatment of inflammation and patholo...
|
|
JP4732693B2 |
The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositio...
|
|
JP4711621B2 |
Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
|
|
JP2011513289A |
Covalent conjugates of an α,α-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylester...
|
|
JP2011512334A |
Compounds according to the formula below are disclosed herein: Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
|
|
JP2011511053A |
The present invention relates to an improved process for the preparation of the active pharmaceutical ingredient, vorinostat. In particular it relates to an efficient process for the preparation of vorinostat of high purity without the r...
|
|
JP4644829B2 |
The present invention is directed to compounds of the general formula (I) or pharmaceutical acceptable salts or physiologically functional derivatives thereof wherein: n is a non-aromatic ring system containing two to seven carbon atoms,...
|
|
JP4648628B2 |
This invention comprises the novel compounds of formula (I) wherein n, m, t, R1, R2, R3, R4, R5, L, Q, X, Y and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing t...
|
|
JP4643267B2 |
The invention relates to 4-propargyloxy-benzyl dervatives of the general formula (I) including the optical isomers thereof and mixtures of such isomers, wherein R1 is hydrogen, optionally substituted alkyl, optionally substituted cycloal...
|
|
JP2011505682A |
Semiconductor processing compositions comprising amidoxime compounds having two or more amidoxime functional groups and their use in semiconductor processing to remove photoresist, polymeric materials, etching residues and copper oxides ...
|
|
JP2011504471A |
The invention relates to novel cyclic hydrocarbon compounds and derivatives thereof, processes for the preparation thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions c...
|
|
JP4625236B2 |
This invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels a...
|
|
JP4619531B2 |
The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to the following formula: wherein R1, R2, R3, R4, X, and Z are as defined. This invention also includes opti...
|
|
JP2011502133A |
This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salt...
|
|
JP4615710B2 |
The present invention relates to diterpene derivatives prepared from the components which are extracted from Acanthopanax Koreanum and represented by Chemical Formula (1).
|
|
JP2011501746A |
Provided herein are novel, stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, metabolites, prodrugs, solvates, pharmaceutically acceptable salts and comp...
|
|
JP4612621B2 |
This invention pertains to certain carbamic acid compounds of the formula (I), which inhibit HDAC (histone deacetylase) activity: wherein: J is a linking functional group and is independently:-O -C(-O)- or -C(-O)-O - or -C(-O)-; Cy is a ...
|
|
JP2010540630A |
The present invention relates to a novel class of N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives. The N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide compounds can be used to...
|
|
JP4563798B2 |
Novel PDF inhibitors and novel methods for their use are provided.
|
|
JP4554926B2 |
A benzophenone derivative represented by the following formula: wherein R<1> represents, for example, an optionally substituted heterocyclic group, or a substituted phenyl group; Z represents, for example, an alkylene group; R<2> represe...
|
|
JP4531865B2 |
A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces ...
|
|
JP4528918B2 |
|
|
JP4518065B2 |
|
|
JP4505329B2 |
This invention relates to class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resor...
|
|
JP4486892B2 |
Novel PDF inhibitors and novel methods for their use are provided.
|
|
JP2010520915A |
The present invention relates to a compound of Formula (I), its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemate, as well as pharmaceutically acceptable salts thereof, whe...
|
|
JP2010513326A |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods f...
|
|
JP2010511622A |
The present invention provides methods of treating stroke comprising administering an effective amount of one or more of certain hydroxylamine derivatives to a subject in need thereof. The invention also provides pharmaceutical compositi...
|
|
JP2010065021A |
To provide a method for producing an acrylate (methacrylate) precursor in high purity.The method for producing the acrylate (methacrylate) precursor such as chloropropionates comprises: a step of reacting an acrylate (methacrylate) deriv...
|
|
JP2010509221A |
The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SA...
|
|
JP4439265B2 |
This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, TNF-alpha or combinations thereof.
|
|
JP4434595B2 |
New metal complexes of iminohydroxamic acids are claimed. New metal complexes (I) of iminohydroxamic acids are of formula (1). Nu = O, S, NR4asterisk, PR4asterisk; M = Ni, Pd; h = 0-4; X = halo, 1-8C alkyl, 3-12C cycloalkyl, 7-13C aralky...
|
|
JP4425905B2 |
Compounds of formula (I), inhibit TNFalpha production and may therefore be useful in the treatment of inflammation, of auto-immune diseases, and of pathological conditions which involve excessive production of that cytokine. The compound...
|
|
JP4424628B2 |
An anti-oxidizing composition for scavenging free radicals, comprising at least one essential oil component containing a number of fat-soluble, low-molecular-weight compounds, a pharmaceutical composition comprising the above composition...
|
|
JP2010504969A |
The present invention provides amine base salts of SAHA, polymorphs and pharmaceutical compositions thereof. The invention provides a method of treating cancer by administering the pharmaceutical composition. The invention also provides ...
|
|
JP2010503615A |
The invention relates to retinoid compounds of the formula or or a salt thereof, and to the use of such compounds in the control of cell differentiation.
|
|
JP2010502743A |
The present invention relates to the compositions, methods, and applications of a novel approach to selective inhibition of several cellular or molecular targets with a single small molecule. More specifically, the present invention rela...
|
|
JP2010006817A |
To provide a hydroxamic acid or carboxylic acid-functional compound (which can inhibit production of a tumor necrosis factor alpha (TNF-)), a pharmaceutical composition containing such a compound and a curing method using such a compound...
|
|
JP4389271B2 |
An N-hydroxyformamidine compound of the following formula or a pharmaceutically acceptable salt thereof: wherein R1, A and R are as defined herein. The compounds inhibit 20-HETE-producing enzymes, 20-HETE being involved in the effects of...
|
|
JP4384617B2 |
The present invention is related to novel intermediates and processes which are useful in the preparation of certain antihistaminic piperidine derivatives of formula (I) wherein W represents -C(=O)- or -CH(OH)-; R 1 represents hydrogen o...
|
|
JPWO2008007780A1 |
Equation (I) (in equation, R1Represents a substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group, and R2Represents a substituted or unsubstituted aryl, a substituted or unsubstituted aromatic hete...
|
|
JP4376970B2 |
The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseas...
|
|
JP4358908B2 |
This invention is directed to compounds of formula I: wherein the variables are as described herein. Compounds within the scope of the present invention possess useful properties, more particularly pharmaceutical properties. They are esp...
|
|
JP4353633B2 |
The invention relates to a method for producing N-acylated (hetero)aromatic hydroxylamine derivatives of formula (I), wherein the substituents, the ring atom and the index have the meanings give in the Description, by hydrogenating a (he...
|
